SCHEMBL2229351

SCHEMBL2229351

CC/C=C\C/C=C\C/C=C\CCCCCCC(C)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.60
F7 P08709 6/20 0.60
F3 P13726 6/20 0.60
CYP19A1 P11511 5/20 0.60
PPARG P37231 5/20 0.60
MAPT P10636 4/20 0.60
OXER1 Q8TDS5 4/20 0.60
PPARD Q03181 4/20 0.60
PPARA Q07869 4/20 0.60
PTGS1 P23219 3/20 0.60
CYP3A4 P08684 3/20 0.60
ALOX15 P16050 3/20 0.60
HSD17B10 Q99714 3/20 0.60
TDP1 Q9NUW8 3/20 0.60
FFAR1 O14842 3/20 0.60
KMT2A Q03164 2/20 0.60
KDM4E B2RXH2 2/20 0.60
LMNA P02545 2/20 0.60
HPGD P15428 2/20 0.60
FFAR4 Q5NUL3 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3213389 1.00 ALDH1A1 (0.60) ALDH1A1F7F3CYP19A1PPARG
SCHEMBL20553455 1.00 ALDH1A1 (0.60) ALDH1A1F7F3CYP19A1PPARG
SCHEMBL2984576 1.00 ALDH1A1 (0.60) ALDH1A1F7F3CYP19A1PPARG
SCHEMBL20553456 1.00 ALDH1A1 (0.60) ALDH1A1F7F3CYP19A1PPARG
SCHEMBL22635677 1.00 ALDH1A1 (0.60) ALDH1A1F7F3CYP19A1PPARG
SCHEMBL2984578 1.00 ALDH1A1 (0.60) ALDH1A1F7F3CYP19A1PPARG
SCHEMBL3224652 0.98 ALDH1A1 (0.57) ALDH1A1F7F3CYP19A1PPARG
SCHEMBL15463523 0.95 F7 (0.51) ALDH1A1F7F3CYP19A1PPARG
SCHEMBL4308676 0.95 F7 (0.51) ALDH1A1F7F3CYP19A1PPARG
SCHEMBL4308674 0.95 F7 (0.51) ALDH1A1F7F3CYP19A1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091047-A1 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS NATIVE CODE BIO LLC (US) 2026-04-02 US claimed
EP-4583856-A2 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS Native Code Bio, LLC (US) 2025-07-16 EP claimed
WO-2024054688-A2 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS NATIVE CODE BIO, LLC (US) 2024-03-14 WO claimed
CN-109971807-B Method for synthesizing polyunsaturated fatty acid starch ester by subcritical fluid system and application thereof 吉林省长德健康产业有限公司 2023-02-07 CN claimed
CN-109824719-B Preparation method of phenylsulfonic-modified SBA-15 composite material and application of phenylsulfonic-modified SBA-15 composite material in synthesis of structured phospholipid 大连工业大学 2021-07-06 CN claimed
CN-109879905-B Preparation method of naphthyl sulfonic group modified SBA-15 and application of naphthyl sulfonic group modified SBA-15 in synthesis of phospholipid rich in unsaturated fatty acid structure 大连工业大学 2021-07-06 CN claimed
EP-3011041-B1 BIODIESEL COMPOSITION AND RELATED PROCESS AND PRODUCTS ARGENT ENERGY UK LTD (GB) 2020-02-19 EP claimed
EP-1478335-B1 PERFUME CONTAINING SURFACTANT COMPOSITIONS HAVING PERFUME BURST WHEN DILUTED AND PROCESS THEREOF UNILEVER PLC (GB) 2014-07-30 EP claimed
EP-2061455-B1 STABILIZED SYNTHETIC BROOD PHEROMONE FOR MANIPULATING THE BEHAVIOUR AND PHYSIOLOGY OF HONEY BEES CONTECH ENTPR INC (CA) 2013-07-17 EP claimed
EP-1584659-B1 Curable silicone composition DOW CORNING TORAY CO LTD (JP) 2008-07-09 EP claimed
EP-1127916-B1 Filler/adhesive agent for display units containing a curable silicone composition DOW CORNING TORAY SILICONE (JP) 2004-09-22 EP claimed
EP-0592577-B1 ANTI-OVIPOSITION COMPOSITIONS INCLUDING A FATTY ACID AND/OR A FATTY ACID ALKYL ESTER AND OPTIONALLY A MONOTERPENE AGRONOMIQUE INST NAT RECH (FR) 1995-10-11 EP claimed
EP-0431942-B1 Percutaneously absorbable pharmaceutical preparation containing dopamine derivative SANSHO CO (JP) 1994-03-23 EP claimed
US-20260091047-A1 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS NATIVE CODE BIO LLC (US) 2026-04-02 US disclosed
EP-4665318-A2 THERAPEUTIC COMBINATIONS FOR INFLAMMATORY CONDITIONS AND DISORDERS Native Code Bio, LLC (US) 2025-12-24 EP disclosed
EP-4583856-A2 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS Native Code Bio, LLC (US) 2025-07-16 EP disclosed
EP-1723098-A1 METHOD FOR THE FUNCTIONALIZATION OF CONJUGATED OR CONJUGATABLE DERIVATIVES ASSISTED BY A TEMPO-TYPE ELECTROPHORIC MEDIATOR Centre National De La Recherche Scientifique-CNRS (FR) 2006-11-22 EP disclosed
WO-2006002867-A1 PRODUCT FOR USE IN PAPERMAKING AND PREPARATION THEREOF CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2006-01-12 WO disclosed
WO-2005097726-A1 METHOD FOR THE FUNCTIONALIZATION OF CONJUGATED OR CONJUGATABLE DERIVATIVES ASSISTED BY A TEMPO-TYPE ELECTROPHORIC MEDIATOR CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE- CNRS (FR) 2005-10-20 WO disclosed
CN-85104633-A Influence compound and the preparation method of composition and the purposes of plant-growth and output 1987-04-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260091047-A1 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS HMBS, SNCA, PYGB ALDH1A1 4409/4885F7 2983/4885F3 4159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.